CClinicalTrials.gg
CompletedNCT06220344Updated Jan 25, 2024

Honey Dressing - A Preventive Procedure for Post-Surgical Site Infection.

A Phase 2/3 interventional study of Honey Dressing and Iodine Dressing in Wound Infection, Wound Dehiscence and Wound Bleeding, sponsored by HITEC-Institute of Medical Sciences. Completed at 1 site in Pakistan. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by HITEC-Institute of Medical Sciences · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2022, registered Jan 2024).
Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
12 Years to 50 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the wound healing in the participants who underwent the clean surgical procedure, by applying honey dressing and common Iodine solution dressing, participants will have no other co-morbidities like Diabetes, Anemia, etc. which can make the results biased. The main questions it aims to answer are:

  • Do the iodine solutions are enough to counter the infections caused by resistant strains of bacteria?
  • What is the efficacy and efficiency of honey dressing in wound care?

Participants will be tasked to

  • Ensure strict follow-up in the hospital dressing room
  • Half of the participants will apply common iodine solution dressing and the other half will be applied honey dressing.

Researchers will compare Iodine dressing (Control group) with Honey dressing (Experimental group) to see if Honey dressing is better in the prevention of post-surgery wound infection and if it is cost-efficient and its efficacy.

02

Conditions studied

03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 80 is below the median of 120 across 4,201 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

HITEC-Institute of Medical Sciences is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Patients with sterile/clean post-surgical wounds are admitted in general surgery, neurosurgery, orthopedic, and gynecology wards and require follow-up dressings.

Exclusion criteria

Exclusion Criteria:

  1. Patients with:

    • Anemia
    • BMI>30
    • Local Infection in wound area.
    • Venous leg ulcers
    • Diabetes
    • Immunocompromised (Oncological patients)
  2. Patient under negative pressure therapy
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Honey

    Participants will get honey dressings in their follow-up visits to the dressing room.

    Biological: Honey Dressing

  • Active comparator
    Aseptic Iodine

    Participants will get iodine solution dressings in their follow-up visits to the dressing room.

    Drug: Iodine Dressing

Interventions

  • BiologicalHoney Dressing

    Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.

  • DrugIodine Dressing

    Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.

    Also known as: Iodine solution dressing

06

What researchers measure

Primary outcomes

  1. Signs of Wound Infection

    Presence of exudate, warmth, pus, erythema, dehiscence, contact bleeding, and any systemic sign like fever, rash, and myalgia.

    Time frame: 3rd day, 7th day, 15th day.

07

Study locations

1 site
  • Heavy Industry Taxila Hospital
    Rawalpindi, Punjab 407070, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06220344
Lead sponsor
HITEC-Institute of Medical Sciences
Responsible party
Syed Muhammad Ali Haider (House Officer Neurosurgery, HITEC-Institute of Medical Sciences) — Principal investigator
First posted
Jan 23, 2024
Start date
Dec 2, 2022
Primary completion
Mar 3, 2023
Completion
Mar 3, 2023
Last update
Jan 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion